|
The company's business plan is based upon addressing the significant underserved
clinical need for hyaline cartilage for use in joint repair. This underserved
need for hyaline cartilage is well established and results in the inability to
adequately treat patients with focal osteochondral defects or osteoarthritis.
The company's technology has
the potential to address markets totaling more than $1 billion. Potential
markets include focal osetochondral defects and osteoarthriris.
In April 2009, Elm Street Ventures invested
$250,000 as part of a $500,000 commitment to the company.
CardioPhotonics
Invented by Dr. Kirk Shelley and and Dr. David
Silverman of Yale, the company's technology provides real-time, non-invasive
blood volume monitoring with readings that are accurate from the first signal
and sensitive to less than a unit of blood, thus providing clinicians with
actionable data, including immediate fluid responsiveness feedback.
The company's goal is to develop an integrated
set of products that are effective across all major causes of fluid volume
change, in both hospital and non-hospital settings.
The company has developed a
working prototype for mechanically ventilated patients that is being used
regularly as part of a Yale clinical investigation. The results to date are
consistent with expectations. Studies and development are
ongoing for spontaneous breathing patients. The data to date is encouraging.
The company's technology has the potential to
address markets totaling $2 billion. Potential markets include hospital surgery,
ICU/CCU, renal dialysis, and cardiac units; emergency room and trauma transport
applications; and military and geriatric markets.
Presented by CURE and the Yale Office of
Cooperative Research, the BioHaven Series thanks its lead sponsors, Wiggin and
Dana and PricewaterhouseCoopers. The series is also sponsored by Elm Street
Ventures, with additional support from the Yale Entrepreneurial Institute and
the Yale Biotechnology & Pharmaceutical Society.
|
